Acorda Therapeutics
- Company typePrivate
- Founded1995
- HeadquartersHawthorne, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
Acorda Therapeutics firmographics
Firmographics- Name
- Acorda Therapeutics
- Legal name
- Acorda Therapeutics Inc.
- Website
- https://acorda.com
- Company type
- Private
- Founded year
- 1995
- Operating status
- Closed
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Acorda Therapeutics industry classification
Industry- Product category
- Neurological Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where Acorda Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Hawthorne
- HQ country
- United States
- HQ region
- North America
Markets served
Acorda Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Acorda Therapeutics product offering
Product offeringCore offering
Acorda Therapeutics is a specialty biopharmaceutical company that develops and commercializes therapies for neurological disorders. Its core offering is INBRIJA, an inhaled levodopa powder indicated for the treatment of OFF episodes in patients with Parkinson's disease. The company historically also marketed Ampyra (dalfampridine) for multiple sclerosis and operated in-house packaging and manufacturing operations, which were divested to Catalent Inc.
Product overview
Acorda Therapeutics is a specialty pharmaceutical company focused on neurological therapies. The company offers INBRIJA (levodopa inhalation powder), a product designed for Parkinson's disease patients experiencing OFF episodes. Historical context indicates Acorda previously operated packaging and manufacturing divisions, which were acquired by Catalent Inc., suggesting a shift toward product-focused operations rather than manufacturing infrastructure.
Differentiator
Problem solved
Functional benefit
Products and services
- INBRIJA
- Ampyra (dalfampridine)
Companies that use Acorda Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Acorda Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Acorda Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Catalent Inc.majorCatalent Inc. acquired Acorda Therapeutics Inc.'s packaging and manufacturing divisions as part of Catalent's expansion into cell and gene therapy manufacturing capabilities.
Recent moves6 records
Expansion highlights2 records
Acorda Therapeutics competitors and assessment
Company assessmentBroad incumbents
- AbbVie: Major pharmaceutical company with a substantial neurology and movement disorders franchise (including Duopa for Parkinson's). Comparable in addressing Parkinson's motor symptoms, though across a much broader portfolio.
- Lundbeck: Global specialty CNS pharmaceutical company with a broad neurology portfolio. Comparable to Acorda as an established CNS-focused commercial organization targeting neurological disorders including Parkinson's.
- UCB: Specialty pharmaceutical company with significant neurology franchise (epilepsy, Parkinson's). Comparable to Acorda as a focused neurology pharma commercializing therapies for chronic CNS conditions.
- Teva Pharmaceutical Industries: Large pharmaceutical company with a significant CNS and movement disorders franchise (including Austedo). Comparable in targeting Parkinson's and other neurology indications, though at a much larger scale.
- Neurocrine Biosciences: Specialty neuroscience company with approved CNS therapies and a pipeline focused on neurological and endocrine disorders. Comparable as a neurology-focused commercial-stage pharma company.
Direct peers
- Bial - Portela & Cª: Portuguese pharmaceutical company specializing in Parkinson's disease treatments (e.g., opicapone). Comparable to Acorda as a focused Parkinson's therapy developer competing in the same disease management space.
- Mitsubishi Tanabe Pharma America: Markets Parkinson's disease therapies in the U.S., including formulations targeting motor symptoms and OFF episodes. Comparable as a Parkinson's-focused specialty pharma competing for the same prescriber base as INBRIJA.
- Adamas Pharmaceuticals: Acquired by Supernus Pharmaceuticals, Adamas developed Gocovri for Parkinson's disease dyskinesia, making it the most direct therapeutic competitor to Acorda's INBRIJA in the Parkinson's symptom-management market.
- Supernus Pharmaceuticals: Specialty CNS pharmaceutical company with an established Parkinson's disease portfolio (now including Adamas assets). Directly comparable to Acorda as a focused neurology specialty pharma commercializing Parkinson's therapies.
Emerging players
- Sage Therapeutics: Specialty CNS biopharmaceutical company developing therapies for neurological disorders. Comparable in therapeutic area focus (CNS specialty pharma) and patient population (chronic neurological conditions), though more pipeline-stage.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights4 records
Customer concentration
Acorda Therapeutics social profiles
Digital presenceAcorda Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Acorda Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
Acorda Therapeutics funding detail
Funding detailFunding overview
Funding rounds11 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Acorda Therapeutics M&A and investment
M&A and investmentM&A4 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Acorda Therapeutics
What does Acorda Therapeutics do?
Acorda Therapeutics is a specialty biopharmaceutical company that develops and commercializes therapies for neurological disorders. Its core offering is INBRIJA, an inhaled levodopa powder indicated for the treatment of OFF episodes in patients with Parkinson's disease. The company historically also marketed Ampyra (dalfampridine) for multiple sclerosis and operated in-house packaging and manufacturing operations, which were divested to Catalent Inc.
When was Acorda Therapeutics founded?
Acorda Therapeutics was founded in 1995. It employs 251 to 500 people.
Where is Acorda Therapeutics based?
Acorda Therapeutics is headquartered in Hawthorne, United States, in the North America region.
Who are Acorda Therapeutics's main competitors?
Broad incumbents on record are AbbVie, Lundbeck, UCB, Teva Pharmaceutical Industries and Neurocrine Biosciences. Direct peers are Bial - Portela & Cª, Mitsubishi Tanabe Pharma America, Adamas Pharmaceuticals and Supernus Pharmaceuticals. Sage Therapeutics is listed as an emerging player.
Does Acorda Therapeutics have an API?
No public API is recorded for Acorda Therapeutics.
What industry is Acorda Therapeutics in?
Acorda Therapeutics's product category is Neurological Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.